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1. Introduction  
Most of the scales we use in clinical psychiatry when measuring mood and anxiety were 
developed more that three decades ago. Thus the Hamilton Anxiety Scale (HAM-A) 
(Hamilton 1969) is still the internationally most used clinician-rated scale within states of 
clinical anxiety, whereas Spielberger’s State Anxiety Scale (Spielberger, Gorsuch & Lushene 
1970) or the Symptom Checklist (SCL-90) (Derogatis et al. 1974) are among the most 
frequently used patient-rated questionnaires. 
In her comprehensive content analysis of the items included in 27 different rating scales or 
questionnaires for clinical anxiety, de Bonis (1974) concluded that the HAM-A seems to 
cover the clinically most representative items for states of generalized anxiety. This can be 
considered in itself as one way of demonstrating the clinical validity of the HAM-A. 
As concerns questionnaires, the Spielberger State Anxiety Scale covers the psychic anxiety 
symptoms whereas the anxiety subscale of the SCL-90 contains more somatic anxiety 
symptoms than psychic anxiety symptoms (Derogatis et al. 1974).  
Although the SCL-90 includes some specific anxiety subscales, e.g., a phobia and an 
obsessive-compulsive (OCD) subscale, these anxiety subscales are also not sufficiently valid. 
The measurement of panic attacks is probably most validly measured in terms of minor 
versus major attacks, i.e. global assessments. The measurement of states of OCD is probably 
most validly measured by the duration of this state of anxiety, e.g. less or more than two 
hours daily. The Anxiety-Symptom-Scale (ASS) is shown in the Appendix as an example of 
a very short screening questionnaire covering the many subtypes of states of anxiety. In the 
following, it is the general state of anxiety as measured archetypically by the HAM-A, and 
by the corresponding self-rating scales that will be treated. 
The psychometric validation of these general anxiety scales became important with 
reference to the classes of drugs most frequently investigated in trials of anti-anxiety 
medication, namely tricyclic antidepressants (e.g., imipramine) versus benzodiazepines 
(e.g., diazepam). Early on, Derogatis et al (1974) demonstrated that whereas imipramine was 
superior to diazepam when using the SCL-90 subscale of depression, no differences were 
obtained when using the SCL-90 anxiety subscale. The landmark study in this respect was 
the study by Rickels et al (1993) which demonstrated that when treating patients with 
generalized anxiety disorder with imipramine versus diazepam in a placebo-controlled, 
randomised trial, imipramine was superior to benzodiazepine on the psychic factor in the 
HAM-A but not on the somatic factor in the HAM-A.  
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These results led to a change in the algorithm of generalized anxiety from DSM-III to DSM-
IV so that the number of somatic anxiety symptoms was reduced. However in the ICD-10 
diagnostic manual (World Health Organization 1993) the number of somatic anxiety 
symptoms outranged the number of psychic anxiety symptoms in the algorithm of 
generalized anxiety disorder. 
The following will treat the specific psychometrically valid methods (principal components 
analysis, factor analysis and item response theory analysis) in order to indicate how to use 
HAM-A and SCL-90 in trials of anti-anxiety drugs. 
2. Methods 
In clinical psychometrics we often describe principal components analysis (PCA) or factor 
analysis (FA) as the classical methods of validation while item response theory analysis 
(IRT) is seen as the modern method (Bech et al. 2011). 
Historically, PCA was published at a later date than Spearman’s two factor models of 
intelligence (Spearman 1904, Spearman 1927), namely by Hotelling (1933). When modifying 
a factor analysis with our sophisticated electronic programs, e.g. SPSS or SAS, we start today 
with PCA and then, if necessary, go for various forms of rotations in the so-called 
exploratory FA (Child 2006). 
IRT analysis is used to evaluate to what extent the total score of a scale is sufficient when 
measuring the clinical effect of anti-anxiety drugs. We have both a parametric IRT model 
(Rasch 1960) and a non-parametric model (Mokken 1971). In the following, only Mokken 
analysis will be referred to. 
3. Results 
3.1 The Hamilton anxiety scale (HAM-A) 
The first version of the HAM-A (Hamilton 1959) consisted of 13 items, whereas the revised 
version (Hamilton 1969) included 14 items (see Appendix). Hamilton released his HAM-A14 
with reference to principal components analysis (PCA) on 115 patients (including patients 
with both primary anxiety states (N = 42) and patients with anxiety secondary to somatic 
disorders (N = 53)). Table 1 shows the results. The first principal component is clearly a 
general factor in which all the 14 items have positive loadings. The second principal 
component is a bi-directional, or dual factor with positive loadings on the psychic 
symptoms of anxiety and negative loadings on the somatic anxiety symptoms. Table 1 also 
shows the results from the study by Pichot et al (1981) on 411 patients from the family 
doctor setting with a mixture of primary and secondary states of anxiety. Pichot et al (1981) 
employed both a PCA approach and an exploratory factor analysis (FA) with varimax 
rotation. Essentially, Pichot et al (1981) found no extra information in the FA with rotation. 
As shown in Table 1, the PCA results of Pichot et al (1981) are very similar to those obtained 
by Hamilton (1969). The first principal component is obviously a general factor while the 
second principal component is a bi-directional factor. In the original publication by Pichot et 
al (1981) the sign of the second principal component loadings is actually the opposite of the 
signs published by Hamilton (1969), but this type of loading (negative and positive) is just a 
technical or topographical issue (Child 2006). The second principal component identified by 
Pichot et al (1981) contrasts psychic versus somatic symptoms of anxiety corresponding to 
Hamilton (1969). 
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Items General factor Dual factor 
 
Hamilton  
(1969) 
Pichot et al 
(1981) 
Hamilton  
(1969) 
Pichot et al 
(1981) 
 
Anxious mood 
 
Tension 
 
Fears 
 
Insomnia 
 
Concentration 
 
Depressed mood 
 
Somatic (muscular) 
 
Somatic (sensory) 
 
Cardiovascular 
 
Respiratory 
 
Gastro-intestinal 
 
Genito-urinary 
 
Other autonomic 
 
Behaviour at interview 
 
0.66 
 
0.83 
 
0.49 
 
0.52 
 
0.69 
 
0.69 
 
0.52 
 
0.73 
 
0.68 
 
0.56 
 
0.66 
 
0.45 
 
0.67 
 
0.60 
 
0.50 
 
0.62 
 
0.45 
 
0.65 
 
0.62 
 
0.66 
 
0.54 
 
0.58 
 
0.53 
 
0.52 
 
0.29 
 
0.33 
 
0.52 
 
0.70 
 
0.50 
 
0.32 
 
0.29 
 
0.05 
 
0.37 
 
0.33 
 
-0.53 
 
-0.30 
 
-0.41 
 
-0.40 
 
-0.16 
 
-0.25 
 
-0.14 
 
0.10 
 
0.39 
 
0.35 
 
0.35 
 
0.26 
 
0.27 
 
0.38 
 
-0.25 
 
- 0.40 
 
- 0.48 
 
-0.43 
 
-0.39 
 
-0.31 
 
-0.30 
 
- 0.09 
Table 1. Principal Component Analysis of the Hamilton Anxiety Scale by Hamilton (1969) 
[N = 115] and Pichot et al (1981) [N = 411] 
The usefulness of this two factor model of the HAM-A14 was demonstrated by Rickels et al 
(1993) in a double-blind, placebo-controlled trial comparing diazepam with imipramine in 
patients with a DSM-III diagnosis of generalized anxiety disorder. Imipramine was found 
superior to diazepam on the psychic anxiety symptoms (Table 1) on HAM-A, while both 
imipramine and diazepam were superior to placebo on the somatic anxiety symptoms 
(Table 1). However, among the psychic anxiety symptoms in HAM-A (Table 1) are such 
items as depressed mood and sleep. 
Clinical validity was examined in a trial focussing on a 6-item HAM-A subscale (HAM-A6) 
comprising five psychic anxiety symptoms (anxious mood, psychic tension, fears, intellectual 
difficulties, and anxious behaviour) and one somatic anxiety symptom (muscular tension) 
(Bech 2007). This group of HAM-A symptoms covering the core symptoms of generalized 
anxiety disorder is in accordance with the study by Snaith et al (1982).  
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The analyses performed by Meoni et al (2001) revealed that the HAM-A6 items were among 
the symptoms in patients with DSM-IV generalized anxiety disorder with the most 
significant discrimination between venlafaxine and placebo. 
The HAM-A6 was compared to the HAM-A14 in order to evaluate the two scales’ 
psychometric validity, using Mokken’s non-parametric IRT model (Bech 2007). In this study 
the four placebo-controlled trials with fixed doses of pregabalin in patients with generalized 
anxiety disorder were combined, and Mokken analysis identified a coefficient of 
homogeneity of 0.35 for HAM-A14 while HAM-A6 reached 0.46 (Bech 2007). A coefficient of 
homogeneity of 0.40 or higher is, in accordance with Mokken (1971), required to able to state 
that the total score of a scale is a sufficient statistic.  
The pregabalin dose-response relationship study was performed on six of the available 
placebo-controlled trials (Bech 2007). One US trial was excluded from the analysis because 
more than 30% of the patients dropped out during the planned trial period of 4 weeks. The 
quality of a trial is, among other things, evaluated by the percentage of patients completing 
the planned short-term study, and 70% is used in this context (Angst et al. 1989). Another 
trial (Montgomery et al. 2006) was excluded because the HAM-A14 baseline mean score was 
higher than the mean score of the other trials (27.4 versus 24.5 (P < 0.01)) and because the 
age of the patients was high (44.0 (12) versus 37.2 (10) (P < 0.01)) (Bech 2007). 
Effect size was used as response criterion in this pooled analysis of the four trials with 
sufficient homogeneity. An effect size of 0.40 or higher was considered to be evidence of a 
clinically significant effect of pregabalin compared to placebo (Bech 2007). A dose of 150 mg 
pregabalin over four weeks proved to obtain an effect size between 0.17 and 0.22 on HAM-
A6; and between 0.24 and 0.38 on HAM-A14, i.e. not clinically significant. In a dose range 
between 200 mg and 450 mg daily, the pregabalin effect size was between 0.44 and 0.55 on 
the HAM-A6 and 0.37 and 0.68 on the HAM-A14. A dose of 600 mg pregabalin daily did not 
increase the effect size, as the range on the HAM-A6 was between 0.36 and 0.50 (Bech 2007).  
The trial excluded from this pooled analysis due to a significantly higher baseline HAM-A14 
and patient age is the study by Montgomery et al (Montgomery et al. 2006). Table 2 shows the 
results after 4 weeks of therapy in the Montgomery et al study (2006), using effect size as 
response criterion. The HAM-A6 effect size of both 400 and 600 mg pregabalin was between 
0.28 and 0.30, while the effect size of 75 mg venlafaxine daily over four weeks reached a level 
of 0.40 (Bech 2007). In Table 2 the effect size for the HAM-A item of sleep is included, here the 
results show that the effect size was clearly above 0.40 for both doses of pregabalin whereas 
the venlafaxine effect size was below 0.40; indicating that venlafaxine is a non-sedating drug. 
 
Treatment 
Effect size 
HAM-A6 HAM-A14 Sleep 
Pregabalin 400 mg daily 
(N = 97) 
0.30 0.38 0.65 
Pregabalin 600 mg daily 
(N = 110) 
0.28 0.31 0.54 
Venlafaxine 75 mg daily 
(N = 113) 
0.40 0.31 0.33 
Table 2. The placebo-controlled trial by Montgomery et al (2006) with two fixed pregabalin 
doses and the active comparator venlafaxine. In the placebo arm N = 101. The results with 
effect size according to Bech (2007)  
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Lydiard et al (2010) have made an analysis of all six placebo-controlled pregabalin trials in 
generalized anxiety disorder, showing the change from baseline to endpoint on the 
individual HAM-A items. This analysis confirmed that no difference was seen between 450 
mg and 600 mg pregabalin daily compared to placebo for the HAM-A6 items. For the HAM-
A14 item of depressed mood, however, 600 mg pregabalin was statistically more effective 
than 450 mg when compared to placebo (P < 0.01 versus P < 0.05), (Lydiard et al. 2010). 
There are still very few instances in which HAM-A6 and HAM-A14 have been used in trials 
with new generation antidepressants in patients with generalized anxiety disorder. An effect 
size of 0.38 was obtained on HAM-A14 in a placebo-controlled trial with sertraline (Allgulander 
et al. 2004). For venlafaxine Mitte et al (2005) obtained an effect size of 0.30 on HAM-A14 when 
pooling five placebo-controlled trials in patients with generalized anxiety disorder. 
For duloxetine we only have one fixed dose trial in a placebo-controlled design in the 
treatment of generalized anxiety disorder over a 9 week period (Koponen et al. 2007). Based 
on the published results it was not possible to calculate effect size correctly (Koponen et al. 
2007). However, the estimation of sample size in the Koponen et al study (2007) was based 
on the assumption that the pooled standard deviation of the change score on HAM-A14 from 
baseline to endpoint was 6.0, and that the difference in mean change score was 2.0 for 
duloxetine minus placebo. In this case, the effect size of 2/6, or 0.33, was accepted, i.e. at the 
level of venlafaxine (Table 2) for the HAM-A. 
3.2 Symptom checklist (SCL-90) 
The most comprehensive anxiety self-rating scale is the Symptom Checklist (SCL-90). 
Hamilton never developed a self-rating scale corresponding to his HAM-A14. The original 
form of the SCL was developed by Parloff et al (1954). Historically, the final version was 
developed by Derogatis et al (1974), while the different subscales were most precisely 
defined by Bech (1993) . In a review Cyr et al (1985) discussed the factor structure of the 
SCL-90, concluding that principal component analysis (PCA) seems to identify the first 
principal component as a general factor, because all the 90 items are more or less positively 
correlated. However, exploratory factor analysis with varimax rotation as performed by 
Lipman et al (1977), obtaining a nine-factor solution, has been used in several studies with 
the SCL-90. The anxiety subscale from this solution has never been accepted as a sufficient 
scale in trials of anti-anxiety drugs. 
When using an unselected sample of patients treated in our Day Hospital at the Psychiatric 
Centre of North Zealand in Denmark (N = 555) we demonstrated with the SCL-90 that PCA 
identified as the first principal component a general factor reflecting that all the 90 items are 
more or less positively correlated (Bech et al. 2010). The second principal component was a 
bi-directional factor with depression items at one pole and anxiety items at the opposite. 
We had previously identified a SCL depression subscale (SCL-D6) with six items 
corresponding to the HAM-D6. Now we selected from the second principal component the 
anxiety items with the highest loadings. When these items had been subjected to another 
PCA, we could demonstrate the contrast between psychic anxiety items and somatic anxiety 
items. This SCL-A20 anxiety subscale is very similar to the HAM-A14. The SCL-D6 and the 
SCL- A20 are shown in the Appendix. 
Table 3 shows the results from a data set obtained by Danish psychiatrists in private practice 
(chaired by Drs. Bodil Andersen, Bettina N. Holm and Niels-Anton Rasmussen) who now 
use the SCL-90 in their daily routine. In Table 3 the four most frequent ICD-10 depression 
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diagnoses are shown at the top. The mean score on the depression scale (SCL-D6) for 
dysthymia is approximately 10; this is the cut-off score for clinical depression. The mean 
scores on SCL-D6 do increase from the category of mild depression to that of severe 
depression (Table 3). With regard to the anxiety subscale (SCL-A20), the cut-off score for 
clinical anxiety is 30. The category of dysthymia obtained a mean score on the SCL-A20 just 
below 30 whereas the mean score for the depression categories increased with increasing 
degree of depression. 
 
Diagnosis 
Code 
Category Number of 
observations 
SCL-D6 SCL-A20 
     
F 34.1 Dysthymia (N = 43) 10.38 29.40 
F 32.0 Depression, mild (N = 192) 11.70 33.00 
F 32.1 Depression, moderate (N = 171) 12.12 34.00 
F 32.2 Depression, severe (N = 52) 13.20 37.00 
F 34.1 Dysthymia (N = 43) 10.38 29.40 
F 43.0 Acute stress reaction (N = 58) 9.36 27.00 
F 41.2 
Mixed 
anxiety/depression 
(N = 28) 9.90 29.00 
F 41.1 
Generalized anxiety 
disorder 
(N = 68) 11.28 36.40 
F 43.1 
Posttraumatic stress 
disorder 
(N = 40) 13.50 43.20 
Table 3. Standardization: SCL-D6: A total score of 10 or more equals clinical depression 
               SCL-A20: A total score of 10 or more equals clinical anxiety  
Table 3 also shows the four most frequent ICD-10 categories for anxiety, namely acute stress 
reaction, mixed anxiety-depression, generalized anxiety disorder, and PTSD (post-traumatic 
stress disorder). On the SCL-D6, the cut-off score of 10 is obtained for GAD and PTSD, but 
not for mixed anxiety-depression which is in accordance with the ICD-10 criteria for this 
category. On the SCL-A20 the cut-off score for clinical depression is obtained for GAD and 
PTSD but not for mixed anxiety-depression, which is in concordance with the ICD-10 
criteria for this category. 
4. Discussion 
Compared to the Hamilton Depression Scale (HAM-D) the Hamilton Anxiety Scale (HAM-
A) has obtained a status as the international standard for anxiety measurement with a major 
impact on the item profiles of generalized anxiety disorder from DSM-IV to DSM-IV. We do 
not yet have the final version of DSM-V. As regards the ICD-10, research with HAM-A14 has 
shown that the category of generalized anxiety disorder according to ICD-10 is too biased in 
favour of the somatic anxiety symptoms. A revision of ICD-10, ICD-11, will be released 
around 2015.  In the mean time the HAM-A14 is the most appropriate measure for 
generalized anxiety research. The HAM-A14 version shown in the Appendix was developed 
with the acceptance of Max Hamilton himself (Bech, Kastrup & Rafaelsen 1986). The correct 
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use of the HAM-A is to focus on the HAM-A6 in which the total score should be considered 
as a sufficient statistic. 
Max Hamilton never constructed a self-rating version of his HAM-A14. The SCL-A20 
included in the Appendix can be considered as a form of self-reported state of anxiety 
corresponding to HAM-A14. As indicated in the Appendix, nine of the symptoms measure 
psychic anxiety and 11 items measure the somatic anxiety syndrome. 
5. Conclusion 
The measurement of states of anxiety by use of symptom rating scales such as the HAM-A14 
is psychometrically most valid in generalized anxiety. Within such states of anxiety the 
factors of psychic anxiety versus somatic anxiety are important. The HAM-A6 covers the 
core items of the DSM-IV syndromes of generalized anxiety with most emphasis on the 
psychic anxiety symptoms. The SCL-A20 is the SCL-90 subscale to most validly cover the 
HAM-A14 symptoms. 
The Anxiety Symptom Scale (ASS) is useful as a screening instrument to cover the whole 
field of anxiety states, including phobia, panic, or OCD.  
6. Appendix 
All the scales shown below are in the public domain. 
1. Anxiety Symptom Scale (ASS) 
2. The Hamilton Anxiety Scale (HAM-A14) 
a. Scoring Sheet 
b. Manual 
3. SCL-D6 
4. SCL-A20 
6.1 Anxiety symptom scale (ASS) 
The following questions ask about how you have been feeling over the past two weeks. Please put a 
tick in the box that is closest to how you have been feeling. 
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When interpreting the ASS, first determine whether Item 10 (symptom impact on daily 
functioning) has a score of 3 or more. If this is the case, then determine which of the nine 
anxiety symptoms has the highest score, and thereafter whether there is a score on the top 
three symptoms; these are the true anxiety symptoms. 
When measuring treatment effect it is of course possible to use the total score. 
6.2 Hamilton anxiety scale  
6.2.1 HAM-A14 Scoring sheet 
 
No. Symptom Score  
1 Anxious mood 0-4  
2 Tension 0-4  
3 Fears 0-4  
4 Insomnia 0-4  
5 Difficulties in concentration and memory 0-4  
6 Depressed mood  0-4  
7 General somatic symptoms (Muscular symptoms)  0-4  
8 General somatic symptoms (Sensory)  0-4  
9 Cardiovascular symptoms 0-4  
10 Respiratory symptoms 0-4  
11 Gastrointestinal symptoms 0-4  
12 Genito-urinary symptoms 0-4  
13 Other autonomic symptoms  0-4  
14 Behaviour during interview 0-4  
 Total score 0-56  
Symptoms scored from 0 to 4 
 
0 = not present  
1 = mild degree 
2 = moderate degree 
3 = marked degree 
4 = maximum degree 
Sum   
  
  6 to 14 = mild anxiety 
15 to 28 = moderate anxiety 
29 to 52 = severe anxiety 
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6.2.2 HAM-A14 Manual  
1. Anxiety  
This item covers the emotional condition of uncertainty about the future, ranging from 
worry, insecurity, irritability, apprehension to overpowering dread. The patient’s report of 
worrying, insecurity, uncertainty, fear and panic, i.e, the psychic, or mental (“central”) 
anxiety experience is to be found significant. 
0: The patient is neither more nor less insecure or irritable than usual.  
1: The patient reports more tension, irritability or feeling more insecure than usual.  
2: The patient expresses more clearly to be in a state of anxiety, apprehension or irritability, 
which he may find difficult to control. It is thus without influence on the patient's daily life, 
because the worrying still is about minor matters  
3: The anxiety or insecurity is at times more difficult to control because the worrying is 
about major injuries or harms which might occur in the future. E.g.: The anxiety may be 
experienced as panic, i.e. overpowering dread. Has occasionally interfered with the patient's 
daily life.  
4: The feeling of dread is present so often that it markedly interferes with the patient's daily 
life.  
2. Tension  
This item includes inability to relax, nervousness, bodily tensions, trembling and restless 
fatigue.  
0: The patient is neither more nor less tense than usual.  
1: The patient indicates to be somewhat more nervous and tense than usual.  
2: The patient expresses clearly to be unable to relax, full of inner unrest which he finds 
difficult to control, but still without influence on the patient's daily life.  
3: The inner unrest and nervousness is so intense or so frequent that it occasionally has 
interfered with the patient's daily work.  
4: Tensions and unrest interfere with the patient's life and work at all times.  
3. Fears  
A type of anxiety that arises when the patient finds himself in special situations. Such 
situations may be open or closed rooms, to queue, to ride a bus or a train. The patient shall 
experience relief by avoiding such situations. It is important to notice at this evaluation, 
whether there has been more phobic anxiety during the present episode than usual.  
0: Not present.  
1: Doubtful if present.  
2: The patient has experienced phobic anxiety, but was able to fight it.  
3: It has been difficult for the patient to fight or overcome his phobic anxiety which has thus 
to a certain extent interfered with the patient's daily life and work.  
4: The phobic anxiety has clearly interfered with the patient's daily life and work.  
4. Insomnia  
This item covers only the patient's subjective experience of sleep length (hours of sleep per 
24-hour-period) and sleep depth (superficial and interrupted sleep versus deep and steady 
sleep). The rating is based on the three preceding nights. Note: Administration of hypnotics 
or sedatives shall be disregarded.  
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0: Usual sleep length and sleep depth.  
1: Sleep length is doubtfully or slightly reduced (e.g.due to difficulties failing asleep), but no 
change in sleep depth.  
2: Sleep depth is now also reduced, sleep being more superficial. Sleep as a whole somewhat 
disturbed.  
3: Sleep duration as well as sleep depth is markedly changed. The broken sleep periods total 
only a few hours per 24-hour-period.  
4: It is here difficult to ascertain sleep duration as sleep depth is so shallow that the patient 
speaks of short periods of slumber or dosing, but no real sleep.  
5. Difficulties in concentration and memory  
This item covers difficulties in concentration, making decisions about everyday matters, and 
memory.  
0: The patient has neither more nor less difficulties in concentration and/or memory than 
usual. 
1: It is doubtful whether the patient has difficulties in concentration and/or memory.  
2: Even with a major effort it is difficult for the patient to concentrate on his daily routine 
work.  
3: More pronounced difficulties with concentration, memory, or descision making. E.g. has 
difficulties to read an article in a newspaper or watch a television programme right through. 
Scores 3 as long as the loss of concentration or poor memory has not clearly influenced the 
interview.  
4: When the patient during the interview has shown difficulty in concentration and/or 
memory, and/or when decisions are reached with considerable delay.  
6. Depressed mood  
This item covers both the verbal and the non-verbal communication of sadness, depression, 
despondency, helplessness and hopelessness.  
0: Natural mood.  
1: When it is doubtful whether the patient is more despondent or sad than usual. E.g. the 
patient indicates vaguely to be more depressed than usual.  
2: When the patient more clearly is concerned with unpleasant experiences, although he still 
is without helplessness or hopelessness.  
3: The patient shows clear non-verbal signs of depression and/or hopelessness.  
4: The patient's remarks on despondency and helplessness or the non-verbal ones dominate 
the interview in which the patient cannot be distracted.  
7. General somatic symptoms (muscular symptoms)  
This item includes weakness, stiffness, soreness merging into real pain, which is more or less 
diffusely localised in the muscles. E.g. jaw ache or neck ache.  
0: The patient is neither more nor less sore or stiff in his muscles than usual.  
1: The patient indicates to be somewhat more sore or stiff in his muscles than usual.  
2: The symptoms have gained the character of pain.  
3: The muscle pains interfere to some extent which the patient's daily life and work.  
4: The muscle pains are present most of the time and interfere clearly with the patient's daily 
life and work.  
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8. General somatic symptoms (sensory symptoms)  
This item includes increased fatigability and weakness merging into real functional 
disturbances of the senses. Including: Tinnitus, blurring of vision, hot and cold flushes and 
prickling sensations.  
0: Not present  
1: It is doubtful whether the patient's indications of pressing or prickling sensations (e.g.,in 
ears, eyes or skin) are more pronounced than usual.  
2: The pressing sensations in the ear reach the character of buzzing in the ears, in the eye as 
visual disturbances, and in the skin as prickling or itching sensations (paraesthesias).  
3: The generalized sensory symptoms interfere to some extent with the patient's daily life 
and work.  
4: The generalized sensory symptoms are present most of the time and interfere clearly with 
the patient's daily life and work.  
9. Cardiovascular symptoms  
This item includes tachycardia, palpitations, oppression, chest pain, throbbing in the blood 
vessels, and feelings of fainting.  
0: Not present.  
1: Doubtful if present.  
2: Cardiovascular symptoms are present, but the patient can still control the symptoms.  
3: The patient has now and again difficulties in controlling the cardiovascular symptoms 
which thus to some extent interfere with the patient's daily life and work.  
4:  The cardiovascular symptoms are present most of the time and interfere clearly with the 
patient's daily life and work.  
10. Respiratory symptoms  
This item includes feelings of constriction or contraction in throat or chest, dyspnoea 
merging into choking sensations and sighing respiration.  
0: Not present.  
1: Doubtful if present.  
2: Respiratory symptoms are present, but the patient can still control the symptoms.  
3: The patient has now and again difficulties in controlling the respiratory symptoms which 
thus to some extent interfere with the patient's daily life and work.  
4: The respiratory symptoms are present most of the time and interfere clearly with the 
patient's daily life and work.  
11. Gastro-intestinal symptoms  
The item includes difficulties in swallowing, "sinking" sensation of the stomach, dyspepsia 
(heartburn or burning sensations in the stomach, abdominal pains related to meals, fullness, 
nausea and vomiting), abdominal rumbling and diarrhoea.  
0: Not present.  
1: Doubtful if present (or doubtful if different from the patient's ordinary gastrointestinal 
sensations).  
2: One or more of the above-mentioned gastro-intestinal symptoms are present, but the 
patient can still control the symptoms.  
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3: The patient has now and again difficulties in controlling the gastrointestinal symptoms 
which thus to some extent interfere with the patient's daily life and work. E.g. tendency of 
losing control over the bowels.  
4: The gastrointestinal symptoms are present most of the time and interfere clearly with the 
patient's daily life and work. E.g. losing control over the bowels.  
12. Genito-urinary symptoms  
This item includes non-organic or psychic symptoms such as frequent or more pressing 
passing of urine, menstrual irregularities, anorgasmia, dyspareunia, premature ejaculation, 
loss of erection.  
0: Not present.  
1: Doubtful if present (or doubtful if different from the ordinary genito-urinary sensations).  
2: One or more of the above-mentioned genito-urinary symptoms are present, but they do 
not interfere with the patient's daily life and work.  
3: The patient has now and again one or more of the above mentioned genito-urinary 
symptoms to such a degree that they to some extent interfere with the patient's daily life and 
work. E.g. tendency to lose control over micturition.  
4: The genito-urinary symptoms are present most of the time and interfere clearly with the 
patient's daily life and work. E.g. losing control over micturition.  
13. Autonomic symptoms  
This item includes dryness of mouth, blushing or pallor, sweating and dizziness. 0: Not present.  
1: Doubtful if present.  
2: One or more of the above-mentioned autonomic symptoms are present, but they do not 
interfere with the patient's daily life and work.  
3: The patient has now and again one or more of the above-mentioned autonomic symptoms 
to such a degree that they to some extent interfere with the patient's daily life and work.  
4: The autonomic symptoms are present most of the time and interfere clearly with the 
patient's daily life and work.  
14. Behaviour at interview  
This item is based on patient behaviour during the interview. Did the patient appear tense, 
nervous, agitated, restless, fidgeting, tremulous, pale, hyperventilating, or sweating?  
On the basis of such observations a global estimate is made:  
0: The patient does not appear anxious.  
1: It is doubtful whether the patient is anxious.  
2: The patient is moderately anxious.  
3: The patient is clearly anxious.  
4: The patient is overwhelmed by anxiety. E.g. shaking and trembling all over.  
6.3 SCL-D6 
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Standardization: 
0 – 6  :  no depression 
7 – 11:  mild depression 
12 – 17: moderate depression 
18 – 24: severe depression 
6.4 SCL-A20 Anxiety scale  
 
During the past week 
including today, how much 
were you bothered by: 
Not at 
all 
A little 
bit 
Moderately 
Quite a 
bit 
Extremely 
31 Worrying too much 
about things? 
0 1 2 3 4 
2 Nervousness or 
shakiness inside? 
0 1 2 3 4 
33 Feeling fearful? 0 1 2 3 4 
57 Feeling tense or keyed 
up? 
0 1 2 3 4 
23 Suddenly scared for no 
reason? 
0 1 2 3 4 
17 Trembling? 0 1 2 3 4 
72 Spells of terror or panic? 0 1 2 3 4 
47 Feeling afraid to travel on 
buses, subways or trains? 
0 1 2 3 4 
25 Feeling afraid to go out 
of your house alone? 
0 1 2 3 4 
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82 Feeling afraid you will 
faint in public? 
0 1 2 3 4 
55 Trouble concentrating? 0 1 2 3 4 
42 Soreness of your 
muscles? 
0 1 2 3 4 
52 Numbness or tingling in 
parts of your body? 
0 1 2 3 4 
49 Hot or cold spells? 0 1 2 3 4 
12 Pains in heart or chest 0 1 2 3 4 
39 Heart pounding or 
racing? 
0 1 2 3 4 
48 Trouble getting your 
breath? 
0 1 2 3 4 
40 Nausea or upset 
stomach? 
0 1 2 3 4 
4 Faintness or dizziness? 0 1 2 3 4 
78 Feeling so restless you 
can’t sit still? 
0 1 2 3 4 
Total score   
Standardization: A score between 20 and 29 is the risk zone of anxiety and a score of 30 or 
more is a clear  clinical anxiety state 
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